Alemtuzumab to Interferon Beta-1a (Rebif) MS (CAMMS32400

ID Number 08-0002

Principal Investigator(s)
Stephen Krieger

Department(s) or Division(s)

The objectives of this study are to compare the safety and efficacy of 2 annual cycles of either 12mg either 12 mg/day or 24 mg/day intravenous (IV) alemtuzumab to 3-times weekly subcutaneous (SC) interferon beta-1a (Rebif®) in patients with active relapsing-remitting multiple sclerosis (RRMS) who have experienced at least 1 relapse during prior treatment with an interferon beta or glatiramer acetate, after having received that therapy for = 6 months.

Contact Information
Shelly Phelps
(212) 241-3391

Recruiting Patients: No